Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0034766 | Endometrium | AEH | negative regulation of ion transmembrane transport | 22/2100 | 109/18723 | 4.39e-03 | 2.89e-02 | 22 |
GO:00603155 | Endometrium | AEH | negative regulation of ryanodine-sensitive calcium-release channel activity | 5/2100 | 11/18723 | 4.56e-03 | 2.95e-02 | 5 |
GO:00105232 | Endometrium | AEH | negative regulation of calcium ion transport into cytosol | 7/2100 | 20/18723 | 4.57e-03 | 2.95e-02 | 7 |
GO:00613375 | Endometrium | AEH | cardiac conduction | 20/2100 | 98/18723 | 5.64e-03 | 3.46e-02 | 20 |
GO:0043271 | Endometrium | AEH | negative regulation of ion transport | 29/2100 | 160/18723 | 6.16e-03 | 3.70e-02 | 29 |
GO:00228986 | Endometrium | AEH | regulation of transmembrane transporter activity | 45/2100 | 278/18723 | 7.34e-03 | 4.18e-02 | 45 |
GO:00484884 | Endometrium | AEH | synaptic vesicle endocytosis | 14/2100 | 62/18723 | 7.72e-03 | 4.33e-02 | 14 |
GO:01402384 | Endometrium | AEH | presynaptic endocytosis | 14/2100 | 62/18723 | 7.72e-03 | 4.33e-02 | 14 |
GO:00108821 | Endometrium | AEH | regulation of cardiac muscle contraction by calcium ion signaling | 8/2100 | 27/18723 | 7.74e-03 | 4.33e-02 | 8 |
GO:0034763 | Endometrium | AEH | negative regulation of transmembrane transport | 26/2100 | 143/18723 | 8.78e-03 | 4.78e-02 | 26 |
GO:1904063 | Endometrium | AEH | negative regulation of cation transmembrane transport | 20/2100 | 102/18723 | 8.88e-03 | 4.82e-02 | 20 |
GO:19040623 | Endometrium | AEH | regulation of cation transmembrane transport | 55/2100 | 357/18723 | 9.18e-03 | 4.96e-02 | 55 |
GO:007259415 | Endometrium | EEC | establishment of protein localization to organelle | 94/2168 | 422/18723 | 2.22e-10 | 2.51e-08 | 94 |
GO:005109817 | Endometrium | EEC | regulation of binding | 83/2168 | 363/18723 | 6.72e-10 | 6.61e-08 | 83 |
GO:004854517 | Endometrium | EEC | response to steroid hormone | 77/2168 | 339/18723 | 3.80e-09 | 2.71e-07 | 77 |
GO:005109917 | Endometrium | EEC | positive regulation of binding | 44/2168 | 173/18723 | 3.08e-07 | 1.27e-05 | 44 |
GO:190165416 | Endometrium | EEC | response to ketone | 46/2168 | 194/18723 | 1.44e-06 | 4.64e-05 | 46 |
GO:007058515 | Endometrium | EEC | protein localization to mitochondrion | 33/2168 | 125/18723 | 3.74e-06 | 1.00e-04 | 33 |
GO:007265515 | Endometrium | EEC | establishment of protein localization to mitochondrion | 32/2168 | 120/18723 | 4.14e-06 | 1.07e-04 | 32 |
GO:005110117 | Endometrium | EEC | regulation of DNA binding | 31/2168 | 118/18723 | 8.11e-06 | 1.81e-04 | 31 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0516718 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0491518 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
hsa0541818 | Breast | Precancer | Fluid shear stress and atherosclerosis | 28/684 | 139/8465 | 4.74e-06 | 6.00e-05 | 4.59e-05 | 28 |
hsa0541718 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa042189 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
hsa05031 | Breast | Precancer | Amphetamine addiction | 14/684 | 69/8465 | 1.05e-03 | 7.35e-03 | 5.63e-03 | 14 |
hsa0516316 | Breast | Precancer | Human cytomegalovirus infection | 32/684 | 225/8465 | 1.13e-03 | 7.57e-03 | 5.80e-03 | 32 |
hsa0497114 | Breast | Precancer | Gastric acid secretion | 13/684 | 76/8465 | 7.35e-03 | 4.07e-02 | 3.12e-02 | 13 |
hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
hsa0516719 | Breast | Precancer | Kaposi sarcoma-associated herpesvirus infection | 36/684 | 194/8465 | 1.68e-06 | 2.53e-05 | 1.94e-05 | 36 |
hsa0491519 | Breast | Precancer | Estrogen signaling pathway | 28/684 | 138/8465 | 4.10e-06 | 5.39e-05 | 4.13e-05 | 28 |
hsa0541819 | Breast | Precancer | Fluid shear stress and atherosclerosis | 28/684 | 139/8465 | 4.74e-06 | 6.00e-05 | 4.59e-05 | 28 |
hsa0541719 | Breast | Precancer | Lipid and atherosclerosis | 37/684 | 215/8465 | 7.64e-06 | 9.29e-05 | 7.12e-05 | 37 |
hsa0421814 | Breast | Precancer | Cellular senescence | 29/684 | 156/8465 | 1.66e-05 | 1.69e-04 | 1.30e-04 | 29 |
hsa050311 | Breast | Precancer | Amphetamine addiction | 14/684 | 69/8465 | 1.05e-03 | 7.35e-03 | 5.63e-03 | 14 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CALM3 | SNV | Missense_Mutation | novel | c.214N>T | p.Met72Leu | p.M72L | P62158 | protein_coding | tolerated_low_confidence(0.66) | benign(0.015) | TCGA-C5-A8YQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
CALM3 | SNV | Missense_Mutation | | c.27N>C | p.Gln9His | p.Q9H | P62158 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.625) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
CALM3 | SNV | Missense_Mutation | novel | c.150N>T | p.Gln50His | p.Q50H | P62158 | protein_coding | deleterious_low_confidence(0.05) | benign(0.054) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
CALM3 | SNV | Missense_Mutation | novel | c.150G>T | p.Gln50His | p.Q50H | P62158 | protein_coding | deleterious_low_confidence(0.05) | benign(0.054) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CALM3 | SNV | Missense_Mutation | novel | c.31G>A | p.Ala11Thr | p.A11T | P62158 | protein_coding | deleterious_low_confidence(0.02) | benign(0.009) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
CALM3 | SNV | Missense_Mutation | novel | c.265G>A | p.Ala89Thr | p.A89T | P62158 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.774) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
CALM3 | SNV | Missense_Mutation | novel | c.107T>C | p.Val36Ala | p.V36A | P62158 | protein_coding | deleterious_low_confidence(0.03) | possibly_damaging(0.842) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CALM3 | SNV | Missense_Mutation | novel | c.319C>T | p.Arg107Cys | p.R107C | P62158 | protein_coding | tolerated_low_confidence(0.07) | benign(0.015) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CALM3 | SNV | Missense_Mutation | novel | c.35A>G | p.Glu12Gly | p.E12G | P62158 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.981) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CALM3 | SNV | Missense_Mutation | novel | c.178G>C | p.Gly60Arg | p.G60R | P62158 | protein_coding | deleterious_low_confidence(0.05) | possibly_damaging(0.654) | TCGA-37-A5EL-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | temodal | PD |